Tag Archives: IP

Intellectual Property problems for personalized medicine

Amid growing interest in personalized medicine that stands to provide patients with better care at reduced costs, legal battles over gene patents ensue, threatening the viability of widespread implementation. On this topic authors Jennifer Gordon, Steve Lendaris and Anna Volftsun (layers at Baker Botts LLP) wrote a very interesting opinion article for The Scientist on the topic. They also examine the barriers to personalized medicine, including a pending decision in the Myriad Genetics case, and Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO’s IP Priorities for 2011

As we start a new year, the BIO Intellectual Property Department has determined their 2011 priorities.  Intellectual Property remains a foundational priority for BIO and our 1100 biotechnology company members. BIO’s IP department has approved the following priorities for 2011: 1) PTO reforms to improve efficient, timely and quality examination 2) Congressional patent reform legislation 3) Improving IP protection in key foreign markets 4) IP legal developments in the courts 5) Protecting the breadth and flexibility of the patent Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,

USPTO Economic Research Agenda

The USPTO has a new Office of the Chief Economist and they have recently published their research agenda. USPTO Economic Research Agenda The OCE is embarking upon an aggressive economic research program to provide evidence on a range of matters relevant to policymaking and the effect of IP on economic outcomes more generally.  These include: (1) Relating IP to economic growth, performance and employment, including:                          (a)  IP and entrepreneurship                                              (b)  IP and wider Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,